CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← KAZIA THERAPEUTICS LTD (KZIA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

KAZIA THERAPEUTICS LTD (KZIA)

Pharmaceutical Preparations · market cap $160M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-01 (est.)
Phase 2
Pipeline
10
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Kazia Therapeutics (KZIA) is a 6-employee oncology company whose lead asset is paxalisib, listed in our data as a Phase 3 candidate in primary CNS lymphoma (PCNSL), with additional glioblastoma, glioma and pediatric-cancer entries. Our data shows cash of $69.5M against a 2025 net loss of $21M. The listed market cap of $6.37B looks inconsistent with that profile, so treat it with caution (see risks).
The catalyst path
  • 2026-12-01 (est.)Phase 2 · PAXALISIBimp 7/10
Pipeline
AssetPhaseIndication
Paxalisib (GDC-0084)Phase 2Glioblastoma, Adult
AbemaciclibPhase 2CDK Gene Mutation
OpdualagPhase 2Childhood Cancer
Temozolomide capsulePhase 2Malignant Primary Gliomas
PAXALISIBPhase 3Primary Central Nervous System Lymphoma
LomustinePhase 3Glioblastoma
AdagrasibPhase 2CDK Gene Mutation
PI3K Inhibitor paxalisibPhase 2CDK Gene Mutation
Irinotecan (drug)Phase 2Childhood Cancer
EntrectinibPhase 2CDK Gene Mutation
Price & technical context
3-month
-57.2%
6-month
-51.0%
12-month
-15.6%
52-wk range
$5.00–$16.90
vs 50-day MA
-30.6%
vs 200-day MA
-41.8%
Realized vol
123.3%
Max drawdown
-90.9%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for KZIA (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.